Download in electronic PDF format for $25



Search the Complete Journal Archives

The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists

Author(s):  Parks Kenneth Chase,Bernard Brian,Cogdill Christopher Blake

Issue:  Sep/Oct 2015 - Volume 19, Number 5
View All Articles in Issue

Abstract:  A high-level assessment of recent U.S. Food and Drug Administration audits of 503A facilities indicates that a regulatory paradigm shift is occurring. Data and rationale further indicates that the agency seems to be taking a proactive approach for how it monitors these facilities. The auditing practices and observations are eerily similar to those which are seen for 503B Outsourcing Facilities, as well as Current Good Manufacturing Practices Drug and Device Manufacture plants. Perhaps the U.S. Food and Drug Administration is attempting to avoid any major medical outbreaks that may stem from under-supervised drug preparation centers. This report presents the rationale that may be behind the U.S. Food and Drug Administration’s motive for increased 503A scrutiny. In addition, new market incentives are also highlighted, as it seems that firms, which are able to maintain good graces with the agency, will be uniquely positioned to obtain greater market share. All signs indicate that for 503A facilities, regulatory compliance may be the key to greater market share.

Related Keywords: Kenneth Chase Parks, PharmD, Brian Bernard, MS, Christopher Blake Cogdill, PharmD, 21 CFR Parts 210 & 211, U.S. Code of Federal Regulations, Drug Quality and Security Act, U.S. Food and Drug Administration, FDA, Current Good Manufacturing Practices, 503A pharmacy, 503B outsourcing facility, standards, drug shortages, new market opportunities, drug safety, interstate commerce, standard operating procedures, material flow, regulations

Related Categories: BUSINESS, LEGAL, PROFESSIONAL ISSUES

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists Parks Kenneth Chase, Bernard Brian, Cogdill Christopher Blake Sep/Oct 2015 377-380 Buy
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr Jul/Aug 2016 351 View Sample
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug Mar/Apr 2017 95-102 Buy
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr Sep/Oct 2017 356 Buy
Standing Together Fixing the Drug Quality and Security Act Miller David G Mar/Apr 2015 104-106 Buy
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr Nov/Dec 2015 487-488 Buy
Documentation: Records and Reports Akers Michael J Sep/Oct 2017 373-380 Buy
Quality Control Analytical Methods: A Summarized Discussion of Current Good Manufacturing Practice Regulations Allen Loyd V Jr May/Jun 2013 210-219 Buy
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Nov/Dec 2016 457-458 Buy
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G Jul/Aug 2015 303-305 Buy